Markets Stocks Economy Crypto Earnings Banking Energy
Home Stocks Feature
Stocks · Exclusive

RBC Starts Everest Group at Outperform, Says Turnaround Makes Stock Cheap

RBC Starts Everest Group at Outperform, Says Turnaround Makes Stock Cheap
Stocks · 2026
Photo · Eleanor Whitfield for Daily Digest Invest
By Eleanor Whitfield Markets Editor-in-Chief Sep 22, 2026 5 min read

RBC Capital Markets has kicked off coverage of Everest Group with an outperform rating and a $455 price target, telling clients the insurer's ongoing overhaul has left its shares looking inexpensive relative to the earnings power the business could generate once the dust settles.

The call rests on two pillars. First, Everest has spent roughly the past year and a half retreating from business lines that were producing volatile, disappointing results. Second, the company generates about $2.1 billion a year in pre-tax net investment income — a steady stream that RBC argues can underpin more consistent returns even if underwriting results wobble.

What Everest actually does — and why underwriting matters

Everest Group is a reinsurer and specialty insurer. In plain terms, it takes on risk that other insurance companies either can't or don't want to hold entirely on their own books. Reinsurance acts as a backstop: a primary insurer sells a policy to a homeowner or a business, then pays part of that premium to a reinsurer to share the risk if a big claim lands.

An insurer's profit comes from two engines. The first is underwriting — the difference between the premiums it collects and the claims it pays out, plus expenses. When that number is positive, the company is said to have a profitable underwriting result. The second is investment income: insurers hold large pools of capital, called the float, and invest it, typically in bonds. That portfolio throws off interest, and at roughly $2.1 billion a year pre-tax, Everest's is a meaningful contributor to the bottom line.

Underwriting is the harder engine to control. Prices in reinsurance move in cycles, and certain lines of business — catastrophe-exposed property, for example — can swing violently from year to year depending on whether a major storm or wildfire hits. That volatility is precisely what Everest has been trying to reduce.

The turnaround: selling businesses and handing off policies

Over the past 18 months, Everest has pulled back from several volatile, underperforming lines. It has done this in two main ways: selling businesses outright, and striking what are known as renewal rights deals. In a renewal rights transaction, another insurer takes over a book of policies — effectively stepping in to renew those customers when their coverage comes up — while the seller exits the business without a messy wind-down.

The goal is a simpler, more predictable underwriting operation. Fewer moving parts means less exposure to the kind of outsized claims that can wipe out a year's profits. For investors, that translates into earnings that are easier to forecast, which in turn can justify a higher valuation multiple. Companies in this position often argue that the market is still pricing them on their old, messier track record — which is essentially RBC's thesis here.

It's a playbook that has appeared elsewhere in the sector. RBC has made a similar argument about another insurer's turnaround story, where a cleaner book of business was seen as opening the door to buybacks and growth.

The risk RBC is flagging

The note isn't without caveats. RBC points to a potential reserve charge in the third quarter. Reserve charges occur when an insurer concludes that the money it set aside to pay future claims on past policies isn't enough, and it has to top up the pot. That hits earnings in the period the charge is taken and can raise questions about how well a company priced its business in earlier years.

Reserve issues are a recurring theme in insurance investing because they're backward-looking: they reflect claims that are still developing on policies written years ago. A single charge doesn't necessarily derail a turnaround, but it can delay the moment when investors feel confident the reset is complete. That tension — improving prospects versus a near-term earnings hit — is likely to be the central debate around the stock in coming quarters.

What it means for investors

For everyday investors, the RBC call is a useful window into how professional analysts think about insurance stocks. Three things are worth watching:

  • Underwriting discipline. Is Everest actually shrinking its exposure to volatile lines, and are the remaining businesses producing consistent underwriting profits? A rising combined ratio — the industry's key measure of claims and expenses against premiums — would suggest the turnaround is stalling.
  • Investment income. The roughly $2.1 billion annual pre-tax figure is a cushion, but it's sensitive to interest rates. If rates fall, reinvesting maturing bonds at lower yields can shrink that stream over time.
  • Reserve development. Any Q3 charge will be scrutinised for size and for whether it signals deeper problems in the exited businesses.

It's also worth remembering what an outperform rating and a price target actually are: one firm's view, based on its own models and assumptions. Analysts are frequently early, late, or simply wrong. A $455 target is not a prediction that the stock will trade there — it's RBC's estimate of fair value if its thesis plays out.

Broader market conditions matter too. Insurers are sensitive to the interest-rate environment, to catastrophe losses, and to the pricing cycle in reinsurance, which has been firming in recent years after a stretch of softer rates. Any shift in those dynamics would affect Everest regardless of how well its internal reset goes.

The takeaway: RBC is betting that Everest's slimmer, less volatile business, combined with a large and reliable investment portfolio, will produce steadier profits than the market currently assumes. The Q3 reserve question is the near-term test of that thesis.

More from this story

Next article · Don't miss

Amgen's Sjogren's Win Lifts Dow as Iran Tensions and Yields Weigh

Amgen's positive trial results lifted the Dow, but rising Treasury yields and Iran tensions kept markets cautious. The Nasdaq edged up while the Dow fell.

Read the story →
Amgen's Sjogren's Win Lifts Dow as Iran Tensions and Yields Weigh